Hixon Zuercher LLC Sells 2,533 Shares of Edwards Lifesciences Co. (NYSE:EW)

Hixon Zuercher LLC cut its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 9.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,084 shares of the medical research company’s stock after selling 2,533 shares during the period. Hixon Zuercher LLC’s holdings in Edwards Lifesciences were worth $1,857,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Algert Global LLC boosted its holdings in Edwards Lifesciences by 38.4% in the second quarter. Algert Global LLC now owns 4,616 shares of the medical research company’s stock valued at $426,000 after acquiring an additional 1,280 shares in the last quarter. Sanctuary Advisors LLC bought a new position in shares of Edwards Lifesciences during the second quarter valued at $8,917,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Edwards Lifesciences in the second quarter worth about $182,000. Centaurus Financial Inc. lifted its position in Edwards Lifesciences by 13.2% in the 2nd quarter. Centaurus Financial Inc. now owns 1,822 shares of the medical research company’s stock valued at $168,000 after acquiring an additional 212 shares in the last quarter. Finally, Jacobs & Co. CA boosted its position in shares of Edwards Lifesciences by 8.7% during the third quarter. Jacobs & Co. CA now owns 122,900 shares of the medical research company’s stock valued at $8,110,000 after buying an additional 9,879 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their price target for the stock from $82.00 to $90.00 in a research note on Monday, December 16th. Morgan Stanley reiterated an “equal weight” rating and issued a $70.00 target price on shares of Edwards Lifesciences in a research report on Friday, October 11th. Truist Financial reaffirmed a “hold” rating and issued a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Robert W. Baird cut their target price on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Finally, Royal Bank of Canada increased their price objective on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research report on Thursday, December 5th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $79.19.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $73.15 on Friday. The business has a 50-day simple moving average of $72.40 and a 200 day simple moving average of $70.07. The stock has a market cap of $43.14 billion, a price-to-earnings ratio of 10.56, a PEG ratio of 3.65 and a beta of 1.11. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Larry L. Wood sold 25,000 shares of the stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the transaction, the insider now directly owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 33,000 shares of company stock valued at $2,195,180 in the last 90 days. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.